In vivo voltammetric monitoring of catecholamine release in subterritories of the nucleus accumbens shell.
Fast-scan cyclic voltammetry (FSCV) at carbon-fiber microelectrodes has been used to demonstrate that sub-second changes in catecholamine concentration occur within the nucleus accumbens (NAc) shell during motivated behaviors, and these fluctuations have been attributed to rapid dopamine signaling. However, FSCV cannot distinguish between dopamine and norepinephrine, and caudal regions of the NAc shell receive noradrenergic projections. Therefore, in the present study, we examined the degree to which norepinephrine contributes to catecholamine release within rostral and caudal portion of NAc shell. Analysis of tissue content revealed that dopamine was the major catecholamine detectable in the rostral NAc shell, whereas both dopamine and norepinephrine were found in the caudal subregion. To examine releasable catecholamines, electrical stimulation was used to evoke release in anesthetized rats with either stimulation of the medial forebrain bundle, a pathway containing both dopaminergic and noradrenergic projections to the NAc, or the ventral tegmental area/substantia nigra, the origin of dopaminergic projections. The catecholamines were distinguished by their responses to different pharmacological agents. The dopamine autoreceptor blocker, raclopride, as well as the monoamine and dopamine transporter blockers, cocaine and GBR 12909, increased evoked catecholamine overflow in both the rostral and caudal NAc shell. The norepinephrine autoreceptor blocker, yohimbine, and the norepinephrine transporter blocker, desipramine, increased catecholamine overflow in the caudal NAc shell without significant alteration of evoked responses in the rostral NAc shell. Thus, the neurochemical and pharmacological results show that norepinephrine signaling is restricted to caudal portions of the NAc shell. Following raclopride and cocaine or raclopride and GBR 12909, robust catecholamine transients were observed within the rostral shell but these were far less apparent in the caudal NAc shell, and they did not occur following yohimbine and desipramine. Taken together, the data demonstrate that catecholamine signals in the rostral NAc shell detected by FSCV are due to change in dopamine transmission.
Park
J
J
Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-3290, USA.
Aragona
B J
BJ
Kile
B M
BM
Carelli
R M
RM
Wightman
R M
RM
D000818:Animals; D002851:Chromatography, High Pressure Liquid; D003042:Cocaine / Q000494:pharmacology; D003891:Desipramine / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism*; D004558:Electric Stimulation; D008297:Male; D008474:Medial Forebrain Bundle / Q000502:physiology; D008839:Microelectrodes; D009434:Neural Pathways / Q000187:drug effects / Q000502:physiology; D009638:Norepinephrine / Q000378:metabolism*; D050484:Norepinephrine Plasma Membrane Transport Proteins / Q000502:physiology; D009714:Nucleus Accumbens / Q000187:drug effects / Q000378:metabolism* / Q000648:ultrastructure; D010879:Piperazines / Q000494:pharmacology; D020891:Raclopride / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011941:Receptors, Adrenergic / Q000502:physiology; D013378:Substantia Nigra / Q000187:drug effects / Q000502:physiology; D009435:Synaptic Transmission / Q000187:drug effects; D017557:Ventral Tegmental Area / Q000187:drug effects / Q000502:physiology
D050484:Norepinephrine Plasma Membrane Transport Proteins; D010879:Piperazines; D011941:Receptors, Adrenergic; D020891:Raclopride; C043425:vanoxerine; D003042:Cocaine; D003891:Desipramine; D004298:Dopamine; D009638:Norepinephrine
J Physiol. 1994 Jul 15;478 ( Pt 2):239-49
7965845
J Neurochem. 2007 Sep;102(5):1691-1702
17484728
J Neurochem. 2006 Jan;96(2):473-81
16336224
Brain Res. 1998 Sep 28;806(2):127-40
9739125
Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11957-62
18689678
Eur J Neurosci. 2007 Oct;26(7):2046-54
17868375
Neuron. 2002 Oct 10;36(2):229-40
12383779
J Physiol. 2007 Nov 1;584(Pt 3):819-34
17761778
J Neurosci. 1994 Jan;14(1):442-50
8283249
Neuropsychopharmacology. 2004 Dec;29(12):2160-7
15257309
Eur J Neurosci. 2009 Dec 3;30(11):2121-33
20128849
Synapse. 2007 Jan;61(1):37-9
17068772
Synapse. 1997 Nov;27(3):230-41
9329158
Drug Alcohol Depend. 1995 May;38(2):95-137
7671769
J Neurosci. 2002 Jan 15;22(2):389-95
11784783
Eur J Neurosci. 2009 Nov;30(10):1889-99
19912327
Physiol Behav. 2004 Aug;82(1):43-7
15234588
Neuroscience. 2008 Jul 31;155(1):250-7
18597947
Nature. 2003 Apr 10;422(6932):614-8
12687000
J Neurochem. 2007 Mar;100(5):1247-56
17241132
J Neurosci. 2009 Feb 11;29(6):1735-42
19211880
Trends Analyt Chem. 2009 Oct 1;28(9):1127-1136
20160977
J Comp Neurol. 2000 May 1;420(2):211-32
10753308
Nature. 1996 Feb 15;379(6566):606-12
8628395
Analyst. 2003 Dec;128(12):1413-9
14737224
Synapse. 1998 Aug;29(4):310-22
9661249
Brain Res Bull. 1982 Jul-Dec;9(1-6):321-53
6816390
Neurosci Lett. 2000 Mar 3;281(1):9-12
10686403
Proc Natl Acad Sci U S A. 2005 Jul 19;102(29):10023-8
16006505
Anal Chem. 1988 Jul 1;60(13):1268-72
3213946
Acta Physiol Scand Suppl. 1971;367:1-48
4109331
J Neurosci. 2008 Aug 27;28(35):8821-31
18753384
Synapse. 1996 Jan;22(1):87-92
8822482
J Neurochem. 2003 Dec;87(5):1284-95
14622108
Anal Chem. 1998 Sep 1;70(17):586A-592A
9737201
Neuroscience. 1998 May;84(2):413-29
9539213
Brain Res. 1992 Jul 31;587(1):137-46
1525644
Synapse. 2003 Apr;48(1):1-9
12557266
Brain Res Rev. 2007 Nov;56(1):27-78
17574681
Anal Chem. 1996 Sep 15;68(18):3180-6
8797378
Anal Chem. 2004 Oct 1;76(19):5697-704
15456288
Eur J Neurosci. 2009 Sep;30(6):1117-27
19735286